Cell and gene therapies (CGTs) are generating seismic shifts in the pharmaceutical landscape by offering disease-targeting, potentially curative solutions. In recent decades, cell and gene
Secukinumab, an IL-17A antagonist, is marketed by Novartis under the brand name Cosentyx®. In 2023, Cosentyx® observed the sales of 5 billion dollars, inclusive of
Pharmaceutical innovation, drug pricing, and patient access to essential medicines must work in a concerted fashion. Factors like: end up spiking the drug prices. Such
The drug products safety, quality and efficacy has repeatedly been the most talked-about topic in the pharmaceutical space. To be approved for marketing, it is
The Ministry of Commerce and Industry released the draft Patents (2nd Amendment) Rules, 2024 on 3rd January 2024. The draft rules focus on establishing a
Biosimilar medicine is a biologic product. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) define a biosimilar product with certain
